The company's worst days might be behind it.

Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving ...

By Rishika Sadam HYDERABAD, India, Dec 3 (Reuters) - Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug ...

Novo Nordisk's Wegovy consumption jumped 70% after price cuts, lifting share in November. Eli Lilly's Mounjaro still led anti ...

There is more to this news than meets the eye.